Status:

WITHDRAWN

Anti-CD3 & Anti-CD7 Ricin A Immunotoxin-Combination for Acute Graft Versus Host Disease

Lead Sponsor:

Henogen

Conditions:

Acute Graft Versus Host Disease

Eligibility:

All Genders

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

In this study, a combination of two T-cell directed antibodies both conjugated to a cell-killing toxin will be evaluated. Previous in vitro studies have demonstrated that this so-called immunotoxin-co...

Detailed Description

"The experimental design is a non-controlled multicentric fixed-dose Phase I/II study. A total of 12 evaluable patients will be enrolled in 4 transplant centers throughout the Netherlands, in a 9 to 1...

Eligibility Criteria

Inclusion

  • Patients suffering from severe acute GVHD (Grade II-IV) progressing after 3 days, or non-improving after 5 days, of prednisolone at 2 mg/kg a day.
  • Age ≥ 18 years.
  • Patients or their guardians should have given written informed consent using forms approved by the Institutional Review Board.

Exclusion

  • Patients receiving concomitant investigational therapeutics/prophylaxis for acute GVHD at the time of enrollment.
  • Patients with histological signs/symptoms suggestive of chronic GVHD.
  • Patients requiring mechanical ventilation, requiring vasopressor support, requiring hemodialysis, having serum creatinine \> 266 μmol/l (\> 3 mg/dl), or having a serum albumin level of 20 g/l or less.
  • Patients having uncontrolled bacterial, viral or fungal infections at the start of therapy.
  • Patients with current evidence of active intrapulmonary disease.
  • Patients with known hypersensitivity to any of the components of the study drug (murine mAb or RTA).
  • Patients who are pregnant, breast feeding, or, if sexually active, unwilling to use effective birth control for the duration of the study.

Key Trial Info

Start Date :

January 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

January 1 2012

Estimated Enrollment :

12 Patients enrolled

Trial Details

Trial ID

NCT00640497

Start Date

January 1 2010

End Date

January 1 2012

Last Update

April 29 2009

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Department of Hematology Radboud University Nijmegen (RUN)

Nijmegen, Netherlands, 6525 GA

2

Department of Hematology Erasmus MC/Daniel den Hoed Cancer CenterGroene Hilledijk

Rotterdam, Netherlands, 3153075 EA

3

L.F. , Department of HematologyUMC Utrecht

Utrecht, Netherlands, 1003584 CX

Anti-CD3 & Anti-CD7 Ricin A Immunotoxin-Combination for Acute Graft Versus Host Disease | DecenTrialz